Sumitomo Dainippon Pharma Oncology Competitors, Revenue, Alternatives and Pricing

Claim your profile


Boston, MA USA
Total Funding:N/A
Lead Investor(s):N/A

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Sumitomo Dainippon Pharma Oncology's estimated annual revenue is currently $25.9M per year.(?)
  • Sumitomo Dainippon Pharma Oncology's estimated revenue per employee is $201,000

Employee Data

  • Sumitomo Dainippon Pharma Oncology has 129 Employees.(?)
  • Sumitomo Dainippon Pharma Oncology grew their employee count by 65% last year.
  • Sumitomo Dainippon Pharma Oncology currently has 1 job openings.

Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, DSP Cancer Institute and Oncology Clinical Development Unit, will collectively be known as Sumitomo Dainippon Pharma Oncology or SDP Oncology. SDP Oncology is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Our robust and diverse pipeline of preclinical and advanced-stage assets spans multiple areas, including oncogenic pathways, survival mechanisms and novel protein interactions, which aim to address unmet clinical needs in oncology. SDP Oncology encompasses discovery research, external innovation, clinical development and commercialization. The company has teams in Lehi, Utah, Tokyo and Osaka, Japan as well as Cambridge, Massachusetts. At SDP Oncology, we believe in the power of science ᅢᄁ¬ツᆲ¬タワ and our people ᅢᄁ¬ツᆲ¬タワ to usher in breakthrough innovation that will positively impact patients with cancer today and for generations to come.